Mercachem and Syncom, two of the leading European drug discovery Contract Research Organizations (CRO), today announced that the two companies are joining forces effective immediately.
The resulting Mercachem-Syncom Group, with more than 300 employees and operations in Nijmegen and Groningen, the Netherlands and Prague, Czech Republic, becomes the premier European mid-sized CRO offering innovative best-in-class chemistry solutions.
Eelco Ebbers, Managing Director of Mercachem comments: “Today’s merger will take our ability to support our customers and projects with fully integrated drug discovery services to the next level. In Syncom we have found the right partner to form a premier mid-sized CRO, small enough to care and large enough to matter. For our customers, the Mercachem-Syncom Group will provide flexible and in best-in-class chemistry solutions, from design and synthesis of small molecule hits, to the delivery of first GMP batches of identified clinical candidates.”
Ton Vries, CEO of Syncom, adds: “We are extremely proud to join forces with Mercachem. The pharmaceutical industry is demanding a huge bandwidth of highly complex chemistry solutions. Mercachem and Syncom share the same cultural and scientific background and both organizations have a longstanding track-record in satisfying the growing outsourcing demand of the industry.”
The complete press release can be downloaded here.